A detailed history of Thrivent Financial For Lutherans transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 47,696 shares of CRSP stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,696
Previous 47,223 1.0%
Holding current value
$2.25 Million
Previous $2.55 Million 12.15%
% of portfolio
0.0%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$44.62 - $62.75 $21,105 - $29,680
473 Added 1.0%
47,696 $2.24 Million
Q2 2024

Aug 13, 2024

BUY
$51.17 - $68.18 $821,329 - $1.09 Million
16,051 Added 51.49%
47,223 $2.55 Million
Q1 2024

May 14, 2024

SELL
$60.67 - $89.12 $409,583 - $601,649
-6,751 Reduced 17.8%
31,172 $2.13 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $159,770 - $298,608
4,137 Added 12.24%
37,923 $2.37 Million
Q3 2023

Nov 14, 2023

SELL
$45.39 - $59.0 $681,621 - $886,003
-15,017 Reduced 30.77%
33,786 $1.53 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $17,431 - $27,175
-401 Reduced 0.81%
48,803 $2.74 Million
Q1 2023

May 17, 2023

SELL
$41.0 - $56.12 $1.21 Million - $1.66 Million
-29,612 Reduced 37.57%
49,204 $2.23 Million
Q4 2022

Feb 08, 2023

BUY
$39.19 - $65.67 $2.1 Million - $3.52 Million
53,608 Added 212.66%
78,816 $3.2 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $253,198 - $347,184
4,144 Added 19.67%
25,208 $1.65 Million
Q2 2022

Aug 16, 2022

BUY
$43.23 - $73.83 $405,583 - $692,673
9,382 Added 80.31%
21,064 $1.28 Million
Q1 2022

May 13, 2022

SELL
$53.19 - $79.24 $1.53 Million - $2.27 Million
-28,702 Reduced 71.07%
11,682 $733,000
Q4 2021

Feb 16, 2022

BUY
$70.09 - $111.29 $2.7 Million - $4.29 Million
38,516 Added 2061.88%
40,384 $3.4 Million
Q3 2021

Nov 15, 2021

SELL
$110.2 - $156.64 $230,097 - $327,064
-2,088 Reduced 52.78%
1,868 $209,000
Q2 2021

Sep 24, 2021

BUY
$100.84 - $161.89 $266,217 - $427,389
2,640 Added 200.61%
3,956 $640,000
Q2 2021

Aug 19, 2021

SELL
$100.84 - $161.89 $127,764 - $205,114
-1,267 Reduced 49.05%
1,316 $213,000
Q1 2021

May 17, 2021

BUY
$110.72 - $210.04 $107,619 - $204,158
972 Added 60.34%
2,583 $315,000
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $128,348 - $279,073
1,611 New
1,611 $247,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.69B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.